索拉菲尼治疗中晚期肝癌的临床疗效及安全性

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma

目的探讨索拉菲尼对中晚期肝癌患者的临床疗效。方法选取2014年1月至2015年7月间收治的84例中晚期肝癌患者,随机数表法分为观察组和对照组,每组42例。对照组42例患者采用经导管肝动脉化疗栓塞术(TACE)治疗,观察组42例患者在对照组治疗基础上口服索拉菲尼治疗,比较两组患者治疗的有效性和安全性。结果治疗后,观察组患者总有效率为83.3%,对照组患者为57.1%,差异有统计学意义(P<0.05)。观察组患者血清AFP和Child-Pugh评分均较对照组患者明显改善,差异有统计学意义(P<0.05)。两组患者不良反应症状均较轻,且均经对症处理好转。结论索拉菲尼治疗中晚期肝癌有利于提高患者的生活质量,不会明显增加治疗中不良反应,其疗效显著,且安全可靠,值得临床应用。

Objective To evaluate the clinical efficacy and safety of sorafenib in patients with advanced liver cancer. Methods 84 patients with advanced hepatocellular carcinoma were included in the study,in which the control group of 42 patients were treated with TACE,while the observation group of 42 patients were treated with sorafenib combined with TACE,and the efficacy and safety between two groups were compared. Results After treatment,the patients in the observation group total effective rate was 83. 3%,significantly higher than the patients,the difference was statistically significant（ P〈0. 05）,and the group of patients with serum AFP was observed and compared with Child-Pugh score in the control group patients had significant improvement,the difference was statistically significant（ P〈0. 05）,the two groups of symptoms of adverse reactions were mild,and are symptomatic treatment improved. Conclusions Sorafenib treatment of advanced liver cancer will help improve the quality of life of patients,the treatment does not significantly increase the adverse reaction,and its effect is significant,and safe,reliable,worthy of clinical application.